CymaBay Therapeutics (CBAY) Stock Forecast, Price & News

CymaBay Therapeutics (NASDAQ:CBAY) Frequently Asked Questions

Is CymaBay Therapeutics a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CymaBay Therapeutics stock.
View analyst ratings for CymaBay Therapeutics or view top-rated stocks.

When is CymaBay Therapeutics' next earnings date?

CymaBay Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for CymaBay Therapeutics.

How were CymaBay Therapeutics' earnings last quarter?

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) issued its earnings results on Thursday, May, 12th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.31) by $0.01. During the same period in the previous year, the firm earned ($0.25) EPS.
View CymaBay Therapeutics' earnings history.

What price target have analysts set for CBAY?

5 brokerages have issued 1-year price objectives for CymaBay Therapeutics' shares. Their forecasts range from $8.00 to $14.00. On average, they anticipate CymaBay Therapeutics' share price to reach $10.67 in the next twelve months. This suggests a possible upside of 475.0% from the stock's current price.
View analysts' price targets for CymaBay Therapeutics or view top-rated stocks among Wall Street analysts.

Who are CymaBay Therapeutics' key executives?

CymaBay Therapeutics' management team includes the following people:

• Mr. Sujal A. Shah, Pres, CEO & Director (Age 49, Pay $820.57k)
• Dr. Charles A. McWherter Ph.D., Chief Scientific Officer (Age 67, Pay $597.89k)
• Mr. Paul T. Quinlan, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 59, Pay $578.82k)
• Mr. Daniel Menold, VP of Fin. (Age 52)
• Mr. Ken Boehm, Sr. VP of HR
• Mr. Patrick J. O'Mara, Sr. VP of Bus. Devel. (Age 61)
• Dr. Robert L. Martin, Sr. VP of Manufacturing & Nonclinical Devel. (Age 60)
• Ms. Klara A. Dickinson-Eason, Chief Regulatory & Quality Assurance Officer (Age 54)
• Ms. Becki Filice, Sr. VP of Portfolio & Product Leadership (Age 61)
• Dr. Dennis D. Kim M.B.A., M.D., MBA, Chief Medical Officer (Age 52)

Who are some of CymaBay Therapeutics' key competitors?

Some companies that are related to CymaBay Therapeutics include Atea Pharmaceuticals (AVIR), AnaptysBio (ANAB), Eagle Pharmaceuticals (EGRX), Vaxxinity (VAXX), Kiniksa Pharmaceuticals (KNSA), Vanda Pharmaceuticals (VNDA), Pharvaris (PHVS), Intercept Pharmaceuticals (ICPT), Tricida (TCDA), POINT Biopharma Global (PNT), Imago BioSciences (IMGO), Rani Therapeutics (RANI), Bicycle Therapeutics (BCYC), Pharming Group (PHAR) and GH Research (GHRS).
View all of CBAY's competitors.

What other stocks do shareholders of CymaBay Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Advanced Micro Devices (AMD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA), Novavax (NVAX), Corbus Pharmaceuticals (CRBP), Energy Transfer (ET) and Viking Therapeutics (VKTX).

What is CymaBay Therapeutics' stock symbol?

CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."

Who are CymaBay Therapeutics' major shareholders?

CymaBay Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (6.46%), Vanguard Group Inc. (4.54%), Nantahala Capital Management LLC (2.24%), State Street Corp (1.60%), JPMorgan Chase & Co. (1.54%) and Affinity Asset Advisors LLC (1.50%).
View institutional ownership trends for CymaBay Therapeutics.

Which institutional investors are selling CymaBay Therapeutics stock?

CBAY stock was sold by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC, JPMorgan Chase & Co., Prosight Management LP, Invesco Ltd., GSA Capital Partners LLP, UBS Group AG, ClariVest Asset Management LLC, and HAP Trading LLC.
View insider buying and selling activity for CymaBay Therapeutics or view top insider-selling stocks.

Which institutional investors are buying CymaBay Therapeutics stock?

CBAY stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Affinity Asset Advisors LLC, Dimensional Fund Advisors LP, BlackRock Inc., Goldman Sachs Group Inc., Northern Trust Corp, Connor Clark & Lunn Investment Management Ltd., and Charles Schwab Investment Management Inc..
View insider buying and selling activity for CymaBay Therapeutics or or view top insider-buying stocks.

How do I buy shares of CymaBay Therapeutics?

Shares of CBAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CymaBay Therapeutics' stock price today?

One share of CBAY stock can currently be purchased for approximately $1.86.

How much money does CymaBay Therapeutics make?

CymaBay Therapeutics has a market capitalization of $157.08 million. The biopharmaceutical company earns $-90 million in net income (profit) each year or ($1.330010) on an earnings per share basis.

How many employees does CymaBay Therapeutics have?

CymaBay Therapeutics employs 59 workers across the globe.

What is CymaBay Therapeutics' official website?

The official website for CymaBay Therapeutics is www.cymabay.com.

How can I contact CymaBay Therapeutics?

CymaBay Therapeutics' mailing address is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at (510) 293-8800, via email at [email protected], or via fax at 510-293-9090.